Atrium Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Accounts Receivable	15	-	-	0.75
Other Receivables	-	0.1	-	-
Receivables	15	0.1	-	0.75
Prepaid Expenses	2.58	1.54	0.48	0.11
Other Current Assets	0.14	1.21	-	-
Total Current Assets	285.57	2.85	0.48	0.86
Property, Plant & Equipment	6.38	5.51	6.7	9.44
Total Assets	292.36	8.35	7.19	10.29
Accounts Payable	0.81	4.4	0.53	0.5
Accrued Expenses	9.07	8.69	1.44	1.5
Current Portion of Leases	2.68	3.67	3.84	3.64
Current Unearned Revenue	9.34	21.64	20.99	28.16
Other Current Liabilities	-	3.4	-	-
Total Current Liabilities	21.91	41.8	26.8	33.8
Long-Term Leases	-	-	2.96	6.21
Long-Term Unearned Revenue	36.35	28.69	37.96	40.9
Other Long-Term Liabilities	-	0.57	0.57	-
Total Liabilities	58.26	71.07	68.29	80.91
Common Stock	0.02	-62.71	-61.11	-70.62
Shareholders' Equity	234.1	-62.71	-61.11	-70.62
Total Liabilities & Equity	292.36	8.35	7.19	10.29
Total Debt	2.68	3.67	6.8	9.85
Net Cash (Debt)	265.17	-3.67	-6.8	-9.85
Net Cash Per Share	15.50	-0.24	-	-
Filing Date Shares Outstanding	17.11	15.51	-	-
Total Common Shares Outstanding	17.11	15.51	-	-
Working Capital	263.66	-38.96	-26.32	-32.95
Book Value Per Share	13.69	-4.04	-	-
Tangible Book Value	234.1	-62.71	-61.11	-70.62
Tangible Book Value Per Share	13.69	-4.04	-	-
Machinery	-	5.57	2.03	1.76
Leasehold Improvements	-	-	0.29	0.29

Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.